Galashiels, Scotland-based specialty pharmaceutical developer ProStrakan says it has completed the purchase of expanded rights to Rectogesic (glyceryl trinitrate ointment, sold as Cellgesic in the USA) and Tostran (testosterone gel) from US drugmaker Cellergy Pharmaceuticals.
The deal, which was for a total cash consideration of $9.0 million, gives the Scottish group key worldwide rights to the products on a royalty and milestone free basis, in addition to related patent estate and intellectual property rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze